Phase 1 N=42 A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Primary: International Myeloma Working Group (IMWG) Response Criteria — 8; 4; 7; 19 participants
Phase 2 N=9 Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Proportion of Confirmed Tumor Responses Defined to be a Partial Response or Better Noted as the Objective Status on Two Consecutive Evaluations — .4; .25 proportion of…
Phase 2 N=54 Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
Relapsed or Refractory Multiple Myeloma
Primary: Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC) — 57.7 percentage of participants
Phase 2 N=25 Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens
Multiple Myeloma
Primary: Overall Response Rate (PR or Better) of Vorinostat in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory MM Refractory to a Previous…
Phase 2 N=51 A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Objective Response Rate (ORR), Defined as the Combined Rate of Complete Response, Partial Response and Minimal Response — 0; 0; 3; 11 percentage patients
Phase 2 N=39 Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma
Multiple Myeloma in Relapse · Stage II Multiple Myeloma · Stage III Multiple Myeloma
Primary: Confirmed Anti-tumor Response Rate (Complete Response and Partial Response) to the Combination of Bevacizumab and Lenalidomide — 64 percentage of participants
Phase 2 N=8 Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Progression-free Survival at 18 Months (PFS18) Defined as the Proportion of Patients Alive and Free From Disease Progression at 18 Months From Study Entry — 0.3750…
Phase 2 N=18 Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant
Refractory Multiple Myeloma · Stage I Multiple Myeloma · Stage II Multiple Myeloma
Primary: Response Rate, Defined as the Number of Patients Achieving Complete Response (CR), Partial Response (PR), or Minor Response (MR) — 5; 2; 3; 1 Participants
Phase 2 N=312 Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Primary: Best Overall Response Rate (ORR) — 16.7; 23.7 % of participants w/ PR or better
Phase 2 N=22 Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Primary: 6B Antibody Response to Prevnar Vaccine in Peripheral Blood — 3.69; 7.58 fold change
Phase 2 N=53 Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants
Phase 2 N=12 Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: MTD, Defined as the Highest Dose in Which =< 1/6 Patients Experience a Dose-limiting Toxicity, Graded According to the National Cancer Institute Common Terminology…
Phase 2 N=64 Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Number of Participants With Dose Limitations Toxicities of the Combination of Lenalidomide and Thalidomide and Dexamethasone (LTD) in Patients With Relapsed/Refractory…
Phase 1 N=86 PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
Multiple Myeloma
Primary: Part 1: Number of Participants With Drug Limiting Toxicities (DLTs) Graded According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE)…
Phase 2 N=40 Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) of Carfilzomib and Pegylated Liposomal Doxorubicin (Phase I - Part 1). — 56; 30 mg/m^2
Phase 2 N=64 Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Primary: The Proportion of Patients Alive and Without Progressive Disease (PD) for ≥6 Months — 75 percentage of treated patients
Phase 2 N=80 Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Primary: Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage — 0; 0; 0; 0 Participants
Phase 2 N=16 Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
Refractory Multiple Myeloma
Primary: Overall Response Rate (ORR) — 4; 7; 5 participants
Phase 2 N=165 Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Proportion of Confirmed Responses With Ixazomib Citrate Alone (Arm A [Closed]), Ixazomib Citrate With Dexamethasone (Arms B + C), or With Dexamethasone and…
Phase 2 N=21 Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Event-free Survival — 29 percentage of participants
Phase 2 N=11 Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Relapsed or Refractory Multiple Myeloma
Primary: Maximally Tolerated Dose — 40 mg
Phase 2 N=157 A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 53; 14; 35 Participants
Phase 2 N=16 Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Refractory Multiple Myeloma
Primary: Number of Confirmed Responses, Defined to be an sCR, CR, VGPR, or PR Noted as the Objective Status on Two Consecutive Evaluations. — 0; 0; 0; 0 participants
Phase 2 N=55 Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Relapsed and Bortezomib Refractory Multiple Myeloma · Refractory Multiple Myeloma · Multiple Myeloma in Relapse
Primary: Overall Response Rate (PR+nCR+CR) — 34.5 percentage of participants
Phase 2 N=20 Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) — 80 mg
Phase 3 N=315 A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Primary: Overall Survival — 10.0; 10.2 months — p=0.4172
Phase 3 N=74 Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Multiple Myeloma
Primary: Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment…
N/A N=295 A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone
Relapsed and/or Refractory Multiple Myeloma
Primary: Progression-Free Survival (PFS) — 4.79 Months
Phase 3 N=255 Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Relapsed/Refractory Multiple Myeloma
Primary: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) — 2.6; 1.7 months — p==0.0054